Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Just In
Mortgage rate relief: Average rate on a 30-year mortgage holds steady at 6.35%, its lowest level since May of 2023
Program
Thursday at 6 on WRAL: ð¦ Hazardous packages on your doorstep. How 1 billion packages from China bypassed safety inspectionsâand why itâs legal.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Travere Therapeutics, Inc.
< Previous
1
2
Next >
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
September 26, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MIRM
TVTX
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report Second Quarter 2023 Financial Results
July 20, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
July 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MIRM
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 08, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
June 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
May 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports First Quarter 2023 Financial Results
May 04, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
May 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report First Quarter 2023 Financial Results
April 26, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
April 01, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
March 28, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
March 23, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
March 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 28, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.